Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization.

ABSTRACT: Red cell alloimmunization may induce severe hemolytic side effects. Identification of risk-modifying conditions will help tailor preventative strategies. This study aims to quantify the associations of hematologic malignancies and solid cancers with red cell alloimmunization in patients receiving red cell transfusions. We performed a nested multicenter case-control study in a source population of 24,063 patients receiving their first and subsequent red cell transfusions during an 8-year follow-up period. Cases (n=505), defined as patients developing a first transfusion-induced red cell alloantibody, were each compared with 2 non-alloimmunized controls (n=1010) who received a similar number of red cell units. Using multivariate logistic regression analyses, we evaluated the association of v

SUBMITTER: Evers D 

PROVIDER: S-EPMC5210232 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature